Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Vir Biotechnology price target raised to $61 from $44 at Barclays » 07:29
08/12/20
08/12
07:29
08/12/20
07:29
VIR

Vir Biotechnology

$52.70 /

-0.49 (-0.92%)

, GILD

Gilead

$68.10 /

-0.43 (-0.63%)

Barclays analyst Gena…

Barclays analyst Gena Wang raised the firm's price target on Vir Biotechnology (VIR) to $61 from $44 and keeps an Overweight rating on the shares after the company's Q2 press release and associated call highlighted progress on the company's COVID-19 antibody programs. Wang, who sees room for meaningful complementary use for COVID-19 antivirals alongside vaccines, looks for data from Vir by year end with a "potentially superior" profile than Gilead's (GILD) remdesivir.

ShowHide Related Items >><<
VIR Vir Biotechnology
$52.70 /

-0.49 (-0.92%)

GILD Gilead
$68.10 /

-0.43 (-0.63%)

VIR Vir Biotechnology
$52.70 /

-0.49 (-0.92%)

05/13/20 Barclays
Vir Biotechnology price target raised to $44 from $41 at Barclays
03/19/20 JPMorgan
JPMorgan downgrades Vir Biotechnology to Underweight after 290% rally
03/19/20 JPMorgan
Vir Biotechnology downgraded to Underweight from Neutral at JPMorgan
03/13/20 Goldman Sachs
Vir Biotechnology downgraded to Neutral from Buy at Goldman Sachs
GILD Gilead
$68.10 /

-0.43 (-0.63%)

08/03/20 Citi
Gilead price target raised to $80 from $78 at Citi
07/31/20 Wells Fargo
Gilead price target lowered to $76 from $87 at Wells Fargo
07/30/20 Piper Sandler
Gilead price target lowered to $85 from $90 at Piper Sandler
07/28/20 Piper Sandler
Piper Sandler lowers FY20, FY21 earnings forecasts for Gilead
VIR Vir Biotechnology
$52.70 /

-0.49 (-0.92%)

GILD Gilead
$68.10 /

-0.43 (-0.63%)

  • 08
    Jul
  • 11
    Oct
VIR Vir Biotechnology
$52.70 /

-0.49 (-0.92%)

GILD Gilead
$68.10 /

-0.43 (-0.63%)

VIR Vir Biotechnology
$52.70 /

-0.49 (-0.92%)

GILD Gilead
$68.10 /

-0.43 (-0.63%)

VIR Vir Biotechnology
$52.70 /

-0.49 (-0.92%)

GILD Gilead
$68.10 /

-0.43 (-0.63%)

Tuesday
On The Fly
Fly Intel: After-Hours Movers » 18:54
08/11/20
08/11
18:54
08/11/20
18:54
CNR

Cornerstone Building Brands

$7.35 /

+0.1 (+1.38%)

, CMBM

Cambium Networks

$11.86 /

-0.31 (-2.55%)

, LRN

K12

$47.31 /

-0.73 (-1.52%)

, AOSL

Alpha & Omega

$11.44 /

+0.12 (+1.06%)

, KODK

Eastman Kodak

$10.01 /

-0.665 (-6.23%)

, CVET

Covetrus

$23.04 /

-0.64 (-2.70%)

, VIR

Vir Biotechnology

$52.70 /

-0.49 (-0.92%)

, TXG

10x Genomics

$96.78 /

+0.01 (+0.01%)

, MRNA

Moderna

$68.94 /

-3.09 (-4.29%)

, FBK

FB Financial

$28.63 /

+0.92 (+3.32%)

, TSLA

Tesla

$1,374.39 /

-45.48 (-3.20%)

, GIII

G-III Apparel

$11.99 /

+0.735 (+6.53%)

, OSPN

OneSpan

$31.19 /

+1.28 (+4.28%)

, IDN

Intellicheck

$8.32 /

+0.08 (+0.97%)

, RRGB

Red Robin

$10.85 /

+0.86 (+8.61%)

, YTEN

Yield10 Bioscience

$6.53 /

+0.38 (+6.18%)

, PLUG

Plug Power

$11.31 /

-0.73 (-6.06%)

, SMCI

Super Micro Computer

$30.45 /

+0.35 (+1.16%)

, HCAT

Health Catalyst

$34.96 /

-0.19 (-0.54%)

, LMND

Lemonade

$62.84 /

-4.44 (-6.60%)

, TRVN

Trevena

$2.72 /

-0.42 (-13.38%)

, PSNL

Personalis

$21.21 /

+0.17 (+0.81%)

, GFF

Griffon

$24.07 /

-0.285 (-1.17%)

, OSTK

Overstock.com

$91.92 /

-3.66 (-3.83%)

, ADVM

Adverum Biotechnologies

$15.59 /

-3.13 (-16.72%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
YTEN Yield10 Bioscience
$6.53 /

+0.38 (+6.18%)

VIR Vir Biotechnology
$52.70 /

-0.49 (-0.92%)

TXG 10x Genomics
$96.78 /

+0.01 (+0.01%)

TSLA Tesla
$1,374.39 /

-45.48 (-3.20%)

TRVN Trevena
$2.72 /

-0.42 (-13.38%)

SMCI Super Micro Computer
$30.45 /

+0.35 (+1.16%)

RRGB Red Robin
$10.85 /

+0.86 (+8.61%)

PSNL Personalis
$21.21 /

+0.17 (+0.81%)

PLUG Plug Power
$11.31 /

-0.73 (-6.06%)

OSTK Overstock.com
$91.92 /

-3.66 (-3.83%)

OSPN OneSpan
$31.19 /

+1.28 (+4.28%)

MRNA Moderna
$68.94 /

-3.09 (-4.29%)

LRN K12
$47.31 /

-0.73 (-1.52%)

LMND Lemonade
$62.84 /

-4.44 (-6.60%)

KODK Eastman Kodak
$10.01 /

-0.665 (-6.23%)

IDN Intellicheck
$8.32 /

+0.08 (+0.97%)

HCAT Health Catalyst
$34.96 /

-0.19 (-0.54%)

GIII G-III Apparel
$11.99 /

+0.735 (+6.53%)

GFF Griffon
$24.07 /

-0.285 (-1.17%)

FBK FB Financial
$28.63 /

+0.92 (+3.32%)

CVET Covetrus
$23.04 /

-0.64 (-2.70%)

CNR Cornerstone Building Brands
$7.35 /

+0.1 (+1.38%)

CMBM Cambium Networks
$11.86 /

-0.31 (-2.55%)

ADVM Adverum Biotechnologies
$15.59 /

-3.13 (-16.72%)

CNR Cornerstone Building Brands
$7.35 /

+0.1 (+1.38%)

06/15/20 Sidoti
Cornerstone Building Brands initiated with a Neutral at Sidoti
03/13/20 DA Davidson
Cornerstone Building Brands upgraded to Neutral at DA Davidson
03/13/20 DA Davidson
Cornerstone Building Brands upgraded to Neutral from Underperform at DA Davidson
11/19/19
Cornerstone Building Brands management to meet with Seaport Global
CMBM Cambium Networks
$11.86 /

-0.31 (-2.55%)

07/21/20 Roth Capital
Cambium Networks price target raised to $16 from $10.50 at Roth Capital
07/02/20 Roth Capital
USF ban for Huawei, ZTE should benefit Cambium, says Roth Capital
06/16/20 JPMorgan
Cambium Networks upgraded to Overweight from Neutral at JPMorgan
06/16/20 JPMorgan
Cambium Networks upgraded to Overweight from Neutral at JPMorgan
LRN K12
$47.31 /

-0.73 (-1.52%)

07/09/20 Sidoti
K12 downgraded to Neutral from Buy at Sidoti
06/04/20 BMO Capital
K12 price target raised to $32 from $30 at BMO Capital
01/28/20 Barrington
K12 price target lowered to $30 from $40 at Barrington
01/28/20 BMO Capital
K12 price target lowered to $23 from $27 at BMO Capital
AOSL Alpha & Omega
$11.44 /

+0.12 (+1.06%)

03/19/20 B. Riley FBR
B. Riley FBR downgrades 10 Semiconductor names on escalating risks
03/19/20 B. Riley FBR
Alpha & Omega downgraded to Neutral from Buy at B. Riley FBR
09/17/19 Loop Capital
Alpha & Omega growth trajectory encouraging, says Loop Capital
08/22/19 Loop Capital
Alpha & Omega price target raised to $18 from $13 at Loop Capital
KODK Eastman Kodak
$10.01 /

-0.665 (-6.23%)

CVET Covetrus
$23.04 /

-0.64 (-2.70%)

06/25/20 Guggenheim
PetIQ price target raised to $44 from $33.50 at Guggenheim
05/18/20 Spin-Off Research
Covetrus upgraded to Buy from Hold at Spin-Off Research
09/09/19 Goldman Sachs
Covetrus initiated with a Sell at Goldman Sachs
08/14/19 Stifel
Covetrus price target lowered to $18 from $30 at Stifel
VIR Vir Biotechnology
$52.70 /

-0.49 (-0.92%)

05/13/20 Barclays
Vir Biotechnology price target raised to $44 from $41 at Barclays
03/19/20 JPMorgan
JPMorgan downgrades Vir Biotechnology to Underweight after 290% rally
03/19/20 JPMorgan
Vir Biotechnology downgraded to Underweight from Neutral at JPMorgan
03/13/20 Goldman Sachs
Vir Biotechnology downgraded to Neutral from Buy at Goldman Sachs
TXG 10x Genomics
$96.78 /

+0.01 (+0.01%)

07/10/20
Fly Intel: Top five analyst initiations
07/09/20 Stifel
10x Genomics initiated with a Buy at Stifel
05/12/20 Cowen
10x Genomics price target raised to $85 from $68 at Cowen
03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
MRNA Moderna
$68.94 /

-3.09 (-4.29%)

08/06/20 Barclays
Moderna COVID vaccine still has 'best-in-class potential,' says Barclays
08/05/20 Piper Sandler
Piper reiterates $134 target on Moderna, notes Q2 ended with $3.1B cash
08/03/20 Jefferies
Moderna's Phase 3 data on COVID vaccine could come by October, says Jefferies
07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
FBK FB Financial
$28.63 /

+0.92 (+3.32%)

01/02/20 Truist
SunTrust raises price targets on select regional banks on improved margins
12/09/19 Sandler O'Neill
FB Financial downgraded to Hold from Buy at Sandler O'Neill
10/23/19 Raymond James
FB Financial downgraded to Market Perform on valuation at Raymond James
10/23/19 Raymond James
FB Financial downgraded to Market Perform from Outperform at Raymond James
TSLA Tesla
$1,374.39 /

-45.48 (-3.20%)

08/05/20 Piper Sandler
Piper calls Beyond Meat the Tesla of packaged food, ups price target
07/29/20 Morgan Stanley
Tesla price target raised to $1,050 from $740 at Morgan Stanley
07/28/20
Fly Intel: Top five analyst downgrades
07/28/20 Bernstein
Bernstein's Sacconaghi downgrades Tesla to sell on 'mind-boggling' valuation
GIII G-III Apparel
$11.99 /

+0.735 (+6.53%)

08/06/20
Fly Intel: Top five analyst downgrades
08/06/20 Barclays
Barclays downgrades G-III Apparel to Underweight on 'secular risk'
08/06/20 Barclays
G-III Apparel downgraded to Underweight from Equal Weight at Barclays
06/08/20
Fly Intel: Top five analyst downgrades
OSPN OneSpan
$31.19 /

+1.28 (+4.28%)

06/24/20 Needham
OneSpan price target raised to $31 from $24 at Needham
05/19/20
Fly Intel: Top five analyst initiations
05/19/20 Needham
OneSpan initiated with a Buy at Needham
05/18/20 Needham
OneSpan initiated with a Buy at Needham
IDN Intellicheck
$8.32 /

+0.08 (+0.97%)

03/12/20 B. Riley FBR
Intellicheck should be bought on recent pullback, says B. Riley FBR
01/08/20 B. Riley FBR
Intellicheck price target raised to $12 from $8 at B. Riley FBR
10/18/19
Fly Intel: Top five analyst initiations
10/18/19 B. Riley FBR
B. Riley FBR starts Intellicheck with Buy rating, $8 price target
RRGB Red Robin
$10.85 /

+0.86 (+8.61%)

06/11/20 Wells Fargo
Red Robin price target lowered to $14 from $30 at Wells Fargo
02/26/20 Wells Fargo
Red Robin price target lowered to $30 from $35 at Wells Fargo
01/15/20 Maxim
Red Robin seeing early signs of turnaround, says Maxim
11/06/19 Loop Capital
Red Robin price target lowered to $33 from $36 at Loop Capital
YTEN Yield10 Bioscience
$6.53 /

+0.38 (+6.18%)

12/11/19 Ladenburg
Yield10 Bioscience price target lowered to $1 from $7 at Ladenburg
11/18/19 National Securities
Yield10 Bioscience downgraded to Neutral from Buy at National Securities
PLUG Plug Power
$11.31 /

-0.73 (-6.06%)

08/03/20 H.C. Wainwright
Plug Power becoming 'go-to solution' for big box retailers, says H.C. Wainwright
07/09/20
Fly Intel: Top five analyst downgrades
07/09/20 Barclays
Plug Power downgraded to Equal Weight on valuation at Barclays
07/09/20 Barclays
Plug Power downgraded to Equal Weight from Overweight at Barclays
SMCI Super Micro Computer
$30.45 /

+0.35 (+1.16%)

06/11/20 Northland
Super Micro Computer initiated with an Outperform at Northland
06/05/20
Fly Intel: Top five analyst initiations
06/05/20 Loop Capital
Super Micro Computer initiated with a Buy at Loop Capital
06/04/20 Loop Capital
Super Micro Computer initiated with a Buy at Loop Capital
HCAT Health Catalyst
$34.96 /

-0.19 (-0.54%)

07/14/20 Citi
Health Catalyst initiated with a Buy at Citi
07/10/20 SVB Leerink
Health Catalyst price target raised to $40 from $32 at SVB Leerink
06/18/20 Stifel
Health Catalyst initiated with a Buy at Stifel
06/15/20 Evercore ISI
Health Catalyst assumed with an Outperform at Evercore ISI
LMND Lemonade
$62.84 /

-4.44 (-6.60%)

07/27/20
Fly Intel: Top five analyst initiations
07/27/20 Oppenheimer
Lemonade initiated with a Perform at Oppenheimer
07/27/20 Goldman Sachs
Lemonade initiated with a Sell at Goldman Sachs
07/27/20 Barclays
Lemonade initiated with an Equal Weight at Barclays
TRVN Trevena
$2.72 /

-0.42 (-13.38%)

09/03/19 H.C. Wainwright
Trevena's oliceridine 'close to the finish line,' says H.C. Wainwright
PSNL Personalis
$21.21 /

+0.17 (+0.81%)

11/14/19 Oppenheimer
Personalis price target lowered to $26 from $29 at Oppenheimer
09/26/19 BofA
Bruker, PerkinElmer, Personalis upgraded to Buy at BofA/Merrill
09/26/19 BofA
Personalis upgraded to Buy from Neutral at BofA/Merrill
GFF Griffon
$24.07 /

-0.285 (-1.17%)

01/14/20 Baird
Griffon upgraded to Outperform at Baird
01/14/20 Baird
Griffon upgraded to Outperform from Neutral at Baird
OSTK Overstock.com
$91.92 /

-3.66 (-3.83%)

07/31/20 DA Davidson
Overstock.com price target raised to $103 from $66 at DA Davidson
07/02/20 DA Davidson
Overstock.com price target raised to $66 from $33 at DA Davidson
05/12/20 Jefferies
Overstock.com 130% sales jump positive for Wayfair, says Jefferies
05/06/20 DA Davidson
Wayfair price target raised to $100 from $45 at DA Davidson
ADVM Adverum Biotechnologies
$15.59 /

-3.13 (-16.72%)

08/10/20 Piper Sandler
Adverum Biotechnologies price target raised to $30 from $25 at Piper Sandler
07/08/20 Cantor Fitzgerald
Adverum Biotechnologies price target raised to $36 from $21 at Cantor Fitzgerald
06/29/20 Piper Sandler
Adverum Biotechnologies should be bought on selloff, says Piper Sandler
06/26/20 Raymond James
Adverum Biotechnologies downgradedat Raymond James on abicipar CRL
YTEN Yield10 Bioscience
$6.53 /

+0.38 (+6.18%)

VIR Vir Biotechnology
$52.70 /

-0.49 (-0.92%)

TXG 10x Genomics
$96.78 /

+0.01 (+0.01%)

TSLA Tesla
$1,374.39 /

-45.48 (-3.20%)

TRVN Trevena
$2.72 /

-0.42 (-13.38%)

SMCI Super Micro Computer
$30.45 /

+0.35 (+1.16%)

RRGB Red Robin
$10.85 /

+0.86 (+8.61%)

PSNL Personalis
$21.21 /

+0.17 (+0.81%)

PLUG Plug Power
$11.31 /

-0.73 (-6.06%)

OSTK Overstock.com
$91.92 /

-3.66 (-3.83%)

OSPN OneSpan
$31.19 /

+1.28 (+4.28%)

MRNA Moderna
$68.94 /

-3.09 (-4.29%)

LRN K12
$47.31 /

-0.73 (-1.52%)

LMND Lemonade
$62.84 /

-4.44 (-6.60%)

KODK Eastman Kodak
$10.01 /

-0.665 (-6.23%)

IDN Intellicheck
$8.32 /

+0.08 (+0.97%)

HCAT Health Catalyst
$34.96 /

-0.19 (-0.54%)

GIII G-III Apparel
$11.99 /

+0.735 (+6.53%)

GFF Griffon
$24.07 /

-0.285 (-1.17%)

FBK FB Financial
$28.63 /

+0.92 (+3.32%)

CVET Covetrus
$23.04 /

-0.64 (-2.70%)

CNR Cornerstone Building Brands
$7.35 /

+0.1 (+1.38%)

CMBM Cambium Networks
$11.86 /

-0.31 (-2.55%)

AOSL Alpha & Omega
$11.44 /

+0.12 (+1.06%)

ADVM Adverum Biotechnologies
$15.59 /

-3.13 (-16.72%)

  • 14
    Aug
  • 12
    Aug
  • 13
    Aug
  • 12
    Aug
  • 12
    Aug
  • 12
    Aug
  • 08
    Jul
  • 02
    Jul
  • 19
    Jun
  • 19
    May
  • 14
    Feb
  • 12
    Feb
  • 12
    Feb
  • 06
    Dec
  • 11
    Oct
  • 12
    Sep
VIR Vir Biotechnology
$52.70 /

-0.49 (-0.92%)

TSLA Tesla
$1,374.39 /

-45.48 (-3.20%)

TRVN Trevena
$2.72 /

-0.42 (-13.38%)

PLUG Plug Power
$11.31 /

-0.73 (-6.06%)

MRNA Moderna
$68.94 /

-3.09 (-4.29%)

LRN K12
$47.31 /

-0.73 (-1.52%)

KODK Eastman Kodak
$10.01 /

-0.665 (-6.23%)

YTEN Yield10 Bioscience
$6.53 /

+0.38 (+6.18%)

VIR Vir Biotechnology
$52.70 /

-0.49 (-0.92%)

TSLA Tesla
$1,374.39 /

-45.48 (-3.20%)

RRGB Red Robin
$10.85 /

+0.86 (+8.61%)

PSNL Personalis
$21.21 /

+0.17 (+0.81%)

PLUG Plug Power
$11.31 /

-0.73 (-6.06%)

OSTK Overstock.com
$91.92 /

-3.66 (-3.83%)

MRNA Moderna
$68.94 /

-3.09 (-4.29%)

LRN K12
$47.31 /

-0.73 (-1.52%)

LMND Lemonade
$62.84 /

-4.44 (-6.60%)

KODK Eastman Kodak
$10.01 /

-0.665 (-6.23%)

IDN Intellicheck
$8.32 /

+0.08 (+0.97%)

HCAT Health Catalyst
$34.96 /

-0.19 (-0.54%)

GIII G-III Apparel
$11.99 /

+0.735 (+6.53%)

FBK FB Financial
$28.63 /

+0.92 (+3.32%)

CVET Covetrus
$23.04 /

-0.64 (-2.70%)

CMBM Cambium Networks
$11.86 /

-0.31 (-2.55%)

AOSL Alpha & Omega
$11.44 /

+0.12 (+1.06%)

ADVM Adverum Biotechnologies
$15.59 /

-3.13 (-16.72%)

VIR Vir Biotechnology
$52.70 /

-0.49 (-0.92%)

TSLA Tesla
$1,374.39 /

-45.48 (-3.20%)

TRVN Trevena
$2.72 /

-0.42 (-13.38%)

SMCI Super Micro Computer
$30.45 /

+0.35 (+1.16%)

RRGB Red Robin
$10.85 /

+0.86 (+8.61%)

PLUG Plug Power
$11.31 /

-0.73 (-6.06%)

OSTK Overstock.com
$91.92 /

-3.66 (-3.83%)

MRNA Moderna
$68.94 /

-3.09 (-4.29%)

LRN K12
$47.31 /

-0.73 (-1.52%)

LMND Lemonade
$62.84 /

-4.44 (-6.60%)

KODK Eastman Kodak
$10.01 /

-0.665 (-6.23%)

FBK FB Financial
$28.63 /

+0.92 (+3.32%)

Earnings
Vir Biotechnology reports Q2 EPS (27c), consensus (62c) » 16:10
08/11/20
08/11
16:10
08/11/20
16:10
VIR

Vir Biotechnology

$52.53 /

-0.66 (-1.24%)

Reports Q2 revenue $67M,…

Reports Q2 revenue $67M, consensus $3.9M. Total revenues for the quarter ended June 30, 2020 were $67.0 million, compared to $2.0 million for same period in 2019. The increase for the quarter was primarily due to $43.3 million related to the license granted to GSK under the collaboration agreement and $22.7 million from Brii Biosciences exercising its option to obtain exclusive rights to develop and commercialize compounds and products arising from VIR-2218 in greater China. "Our organization is uniquely positioned and working rapidly to address the urgent need for solutions to the global COVID-19 pandemic" said George Scangos, Ph.D., chief executive officer of Vir. "We plan to enter the clinic with VIR-7831 in August and have prepared for success by putting in place multiple manufacturing, development, and commercialization agreements to rapidly provide access if approved. In addition, we have continued to execute on our other pipeline priorities, starting two new hepatitis B trials and preparing to start new influenza A and HIV trials. We also further strengthened our balance sheet through a successful follow-on offering."

ShowHide Related Items >><<
VIR Vir Biotechnology
$52.53 /

-0.66 (-1.24%)

VIR Vir Biotechnology
$52.53 /

-0.66 (-1.24%)

05/13/20 Barclays
Vir Biotechnology price target raised to $44 from $41 at Barclays
03/19/20 JPMorgan
JPMorgan downgrades Vir Biotechnology to Underweight after 290% rally
03/19/20 JPMorgan
Vir Biotechnology downgraded to Underweight from Neutral at JPMorgan
03/13/20 Goldman Sachs
Vir Biotechnology downgraded to Neutral from Buy at Goldman Sachs
VIR Vir Biotechnology
$52.53 /

-0.66 (-1.24%)

  • 08
    Jul
  • 11
    Oct
VIR Vir Biotechnology
$52.53 /

-0.66 (-1.24%)

VIR Vir Biotechnology
$52.53 /

-0.66 (-1.24%)

VIR Vir Biotechnology
$52.53 /

-0.66 (-1.24%)

Over a month ago
Syndicate
Vir Biotechnology 7.14M share Secondary priced at $42.00 » 22:38
07/07/20
07/07
22:38
07/07/20
22:38
VIR

Vir Biotechnology

$44.48 /

+3.43 (+8.36%)

The deal size was…

The deal size was increased to 7.14M shares of common stock from 6.2M shares of common stock. Goldman Sachs, BofA, Cowen and Barclays acted as joint book running managers for the offering.

ShowHide Related Items >><<
VIR Vir Biotechnology
$44.48 /

+3.43 (+8.36%)

VIR Vir Biotechnology
$44.48 /

+3.43 (+8.36%)

05/13/20 Barclays
Vir Biotechnology price target raised to $44 from $41 at Barclays
03/19/20 JPMorgan
JPMorgan downgrades Vir Biotechnology to Underweight after 290% rally
03/19/20 JPMorgan
Vir Biotechnology downgraded to Underweight from Neutral at JPMorgan
03/13/20 Goldman Sachs
Vir Biotechnology downgraded to Neutral from Buy at Goldman Sachs
VIR Vir Biotechnology
$44.48 /

+3.43 (+8.36%)

  • 08
    Jul
  • 11
    Oct
VIR Vir Biotechnology
$44.48 /

+3.43 (+8.36%)

VIR Vir Biotechnology
$44.48 /

+3.43 (+8.36%)

VIR Vir Biotechnology
$44.48 /

+3.43 (+8.36%)

Syndicate
Vir Biotechnology 7.14M share Secondary priced at $42.00 » 22:37
07/07/20
07/07
22:37
07/07/20
22:37
VIR

Vir Biotechnology

$44.48 /

+3.43 (+8.36%)

The deal size was…

The deal size was increased to 7.14M shares of common stock from 6.2M shares of common stock. Goldman Sachs, BofA, Cowen and Barclays acted as joint book running managers for the offering.

ShowHide Related Items >><<
VIR Vir Biotechnology
$44.48 /

+3.43 (+8.36%)

VIR Vir Biotechnology
$44.48 /

+3.43 (+8.36%)

05/13/20 Barclays
Vir Biotechnology price target raised to $44 from $41 at Barclays
03/19/20 JPMorgan
JPMorgan downgrades Vir Biotechnology to Underweight after 290% rally
03/19/20 JPMorgan
Vir Biotechnology downgraded to Underweight from Neutral at JPMorgan
03/13/20 Goldman Sachs
Vir Biotechnology downgraded to Neutral from Buy at Goldman Sachs
VIR Vir Biotechnology
$44.48 /

+3.43 (+8.36%)

  • 08
    Jul
  • 11
    Oct
VIR Vir Biotechnology
$44.48 /

+3.43 (+8.36%)

VIR Vir Biotechnology
$44.48 /

+3.43 (+8.36%)

VIR Vir Biotechnology
$44.48 /

+3.43 (+8.36%)

Syndicate
Vir Biotechnology files to sell 6.2M shares of common stock » 07:02
07/06/20
07/06
07:02
07/06/20
07:02
VIR

Vir Biotechnology

$40.27 /

+0.65 (+1.64%)

Goldman Sachs & Co.…

Goldman Sachs & Co. LLC, BofA Securities, Cowen and Barclays are acting as joint book-running managers for the proposed offering. Needham & Company is acting as lead-manager for the proposed offering.

ShowHide Related Items >><<
VIR Vir Biotechnology
$40.27 /

+0.65 (+1.64%)

VIR Vir Biotechnology
$40.27 /

+0.65 (+1.64%)

05/13/20 Barclays
Vir Biotechnology price target raised to $44 from $41 at Barclays
03/19/20 JPMorgan
JPMorgan downgrades Vir Biotechnology to Underweight after 290% rally
03/19/20 JPMorgan
Vir Biotechnology downgraded to Underweight from Neutral at JPMorgan
03/13/20 Goldman Sachs
Vir Biotechnology downgraded to Neutral from Buy at Goldman Sachs
VIR Vir Biotechnology
$40.27 /

+0.65 (+1.64%)

  • 11
    Oct
VIR Vir Biotechnology
$40.27 /

+0.65 (+1.64%)

VIR Vir Biotechnology
$40.27 /

+0.65 (+1.64%)

VIR Vir Biotechnology
$40.27 /

+0.65 (+1.64%)

Hot Stocks
Fly Intel: Top five weekend stock stories » 19:57
06/07/20
06/07
19:57
06/07/20
19:57
AZN

AstraZeneca

$53.87 /

+ (+0.00%)

, GILD

Gilead

$76.67 /

-0.85 (-1.10%)

, FB

Facebook

$230.64 /

+4.38 (+1.94%)

, MRNA

Moderna

$58.16 /

-2.44 (-4.03%)

, NVAX

Novavax

$46.22 /

+1.54 (+3.45%)

, LLY

Eli Lilly

$149.21 /

-1.44 (-0.96%)

, REGN

Regeneron

$597.27 /

-0.94 (-0.16%)

, VIR

Vir Biotechnology

$33.16 /

-1.06 (-3.10%)

, GSK

GlaxoSmithKline

$41.69 /

+0.04 (+0.10%)

, NYT

New York Times

$41.50 /

+1 (+2.47%)

, TWTR

Twitter

$34.86 /

+1.13 (+3.35%)

, FMC

FMC Corporation

$103.29 /

+3.59 (+3.60%)

, SYY

Sysco

$61.60 /

+3.02 (+5.16%)

, USFD

US Foods

$23.36 /

+2.245 (+10.63%)

, PFGC

Performance Food Group

$31.41 /

+3.135 (+11.09%)

, MGP

MGM Growth

$29.02 /

-0.085 (-0.29%)

Catch up on the…

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. AstraZeneca (AZN) has made a preliminary approach to rival drugmaker Gilead Sciences (GILD) about a potential merger, in what would be the biggest health-care deal on record, Bloomberg's Ed Hammond, Aaron Kirchfeld, and Dinesh Nair reported, citing people familiar with the matter. The U.K.-based company informally contacted Gilead last month to gauge its interest in a possible tie-up, the people said. While Gilead has discussed the idea with advisers, no decisions have been made on how to proceed and the companies aren't in formal talks, sources added. 2. Facebook (FB) CEO Mark Zuckerberg said that the company will review existing policies on how it handles content related to civil unrest or violence, as the company faces criticism over its decision to not moderate or take down some posts, The Wall Street Journal's Kimberly Chin reported. Facebook said it will review its policies on content concerning threats of state use of force as well as content in countries with civil unrest or violent conflicts, the author noted. While the company has some policies in place that call for greater restrictions during emergencies and countries undergoing conflict, "there may be additional policies or integrity measures to consider around discussion or threats of state use of force when a country is in this state," Zuckerberg said. 3. Chasing COVID-19 vaccine news has sent investors on a wild ride this spring, as shares of biotechs like Moderna (MRNA) and Novavax (NVAX) have spiked one day and crashed the next, Josh Nathan-Kazis wrote in this week's edition of Barron's. Over the next few months, a handful of pharmaceutical companies plan to begin testing a new category of drugs designed to treat, or even prevent, a COVID-19 infection. Called monoclonal antibodies, the drugs mimic the proteins a human body would make to fight the virus that causes COVID-19, and while they don't hold out the promise of eliminating the threat of COVID-19 in the way that an effective vaccine could, the new antibodies could help curb the pandemic, he noted. This summer, at least three programs aim to begin testing their antibodies in humans, namely Eli Lilly (LLY), Regeneron Pharmaceuticals (REGN), and a collaboration between Vir Biotechnology (VIR) and GlaxoSmithKline (GSK). 4. The New York Times (NYT) said that its editorial page editor James Bennet has resigned following public furor over the paper's decision to publish an op-ed by Republican Senator Tom Cotton under the headline "Send in the Troops," Bloomberg's Yuegi Yang reported. Bennet's deputy, James Dao, will resign from the paper's masthead and be reassigned to the newsroom, the author noted. 5. Twitter (TWTR), FMC (FMC), Sysco (SYY), US Foods (USFD), Performance Food Group (PFGC), MGM Growth Properties (MGP), and GlaxoSmithKline saw positive mentions in this week's edition of Barron's.

ShowHide Related Items >><<
VIR Vir Biotechnology
$33.16 /

-1.06 (-3.10%)

USFD US Foods
$23.36 /

+2.245 (+10.63%)

TWTR Twitter
$34.86 /

+1.13 (+3.35%)

SYY Sysco
$61.60 /

+3.02 (+5.16%)

REGN Regeneron
$597.27 /

-0.94 (-0.16%)

PFGC Performance Food Group
$31.41 /

+3.135 (+11.09%)

NYT New York Times
$41.50 /

+1 (+2.47%)

NVAX Novavax
$46.22 /

+1.54 (+3.45%)

MRNA Moderna
$58.16 /

-2.44 (-4.03%)

MGP MGM Growth
$29.02 /

-0.085 (-0.29%)

LLY Eli Lilly
$149.21 /

-1.44 (-0.96%)

GSK GlaxoSmithKline
$41.69 /

+0.04 (+0.10%)

GILD Gilead
$76.67 /

-0.85 (-1.10%)

FMC FMC Corporation
$103.29 /

+3.59 (+3.60%)

FB Facebook
$230.64 /

+4.38 (+1.94%)

AZN AstraZeneca
$53.87 /

+ (+0.00%)

AZN AstraZeneca
$53.87 /

+ (+0.00%)

06/04/20 UBS
AstraZeneca price target raised to 7,300 GBp from 6,000 GBp at UBS
06/01/20 Piper Sandler
Aveo's tivozanib could launch in U.S. next year, says Piper Sandler
05/29/20 Guggenheim
AstraZeneca price target raised to 10,100 GBp from 9,100 GBp at Guggenheim
05/14/20 Evercore ISI
Evercore ISI says paper 'generally supportive' of AstraZeneca COVID vaccine
GILD Gilead
$76.67 /

-0.85 (-1.10%)

06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/03/20 SVB Leerink
Gilead upgraded to Outperform from Market Perform at SVB Leerink
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
06/01/20 Piper Sandler
Remdesivir now proven effective for COVID-19 in three studies, says Piper
FB Facebook
$230.64 /

+4.38 (+1.94%)

05/29/20 Baird
Twitter, Facebook pullbacks would likely be buying opportunities, says Baird
05/29/20 JPMorgan
Trump order may put 'overhang' on big tech in coming months, says JPMorgan
05/27/20 Cowen
Cowen says Twitter 'will be fine,' but Republicans could support Facebook suit
05/27/20 Citi
Facebook price target raised to $275 from $245 at Citi
MRNA Moderna
$58.16 /

-2.44 (-4.03%)

06/02/20 Piper Sandler
Piper reiterates Overweight rating, $100 target for Moderna after Science Day
06/02/20 BofA
Moderna price target lowered to $75 from $80 at BofA
06/01/20 Goldman Sachs
Goldman keeps $105 target after Moderna COVID vaccine moves to Phase 2
05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
NVAX Novavax
$46.22 /

+1.54 (+3.45%)

06/05/20
Fly Intel: Top five analyst upgrades
06/05/20 JPMorgan
JPMorgan upgrades Novavax to Neutral despite 'shaky fundamentals'
06/05/20 B. Riley FBR
Novavax price target raised to $74 from $61 at B. Riley FBR
06/05/20 JPMorgan
Novavax upgraded to Neutral from Underweight at JPMorgan
LLY Eli Lilly
$149.21 /

-1.44 (-0.96%)

06/05/20 Piper Sandler
Nektar sees 'encouraging trends' in early lupus trial, says Piper Sandler
06/02/20 JPMorgan
JPMorgan positions for second half with three picks in Major Pharma
06/01/20 Morgan Stanley
Lilly trial has higher risk and reward after Pfizer failure, says Morgan Stanley
05/29/20 Raymond James
Blueprint approval for pralsetinib could come before PDUFA, says Raymond James
REGN Regeneron
$597.27 /

-0.94 (-0.16%)

06/02/20 Cantor Fitzgerald
Regeneron price target raised to $624 from $400 at Cantor Fitzgerald
05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Barclays
Regeneron price target raised to $615 from $530 at Barclays
05/27/20 Citi
BioMarin a good takeout candidate, but not by Sanofi, says Citi
VIR Vir Biotechnology
$33.16 /

-1.06 (-3.10%)

05/13/20 Barclays
Vir Biotechnology price target raised to $44 from $41 at Barclays
03/19/20 JPMorgan
JPMorgan downgrades Vir Biotechnology to Underweight after 290% rally
03/19/20 JPMorgan
Vir Biotechnology downgraded to Underweight from Neutral at JPMorgan
03/13/20 Goldman Sachs
Vir Biotechnology downgraded to Neutral from Buy at Goldman Sachs
GSK GlaxoSmithKline
$41.69 /

+0.04 (+0.10%)

05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
05/05/20 JPMorgan
GlaxoSmithKline price target lowered to 1,700 GBp from 1,750 GBp at JPMorgan
04/30/20 Barclays
GlaxoSmithKline price target raised to 1,550 GBp from 1,450 GBp at Barclays
03/11/20 JPMorgan
JPMorgan backs Neutral on GSK after 2019 annual report
NYT New York Times
$41.50 /

+1 (+2.47%)

04/23/20 Evercore ISI
New York Times downgraded to In Line from Outperform at Evercore ISI
11/07/19 JPMorgan
New York Times earnings selloff a 'great buying opportunity,' says JPMorgan
10/09/19
Fly Intel: Top five analyst initiations
10/09/19 Guggenheim
New York Times initiated with a Neutral at Guggenheim
TWTR Twitter
$34.86 /

+1.13 (+3.35%)

05/06/20 China Renaissance
Twitter price target lowered to $23 from $25 at China Renaissance
FMC FMC Corporation
$103.29 /

+3.59 (+3.60%)

05/22/20 Jefferies
Jefferies adds six names to Franchise Picks list, including BioMarin and TJX
05/07/20 KeyBanc
FMC Corporation price target raised to $108 from $93 at KeyBanc
05/07/20 Citi
FMC Corporation price target raised to $114 from $107 at Citi
04/06/20 Truist
FMC Corporation price target lowered to $106 from $125 at SunTrust
SYY Sysco
$61.60 /

+3.02 (+5.16%)

06/05/20 Wells Fargo
Sysco upgraded to Overweight from Equal Weight at Wells Fargo
06/05/20 Wells Fargo
Sysco upgraded to Overweight from Equal Weight at Wells Fargo
06/01/20 Piper Sandler
Sysco upgraded to Overweight from Neutral at Piper Sandler
USFD US Foods
$23.36 /

+2.245 (+10.63%)

05/18/20 Guggenheim
US Foods price target lowered to $30 from $50 at Guggenheim
04/27/20 Credit Suisse
US Foods price target lowered to $27 from $47 at Credit Suisse
04/23/20 BMO Capital
US Foods downgraded to Market Perform from Outperform at BMO Capital
04/06/20 JPMorgan
US Foods price target lowered to $24 from $45 at JPMorgan
PFGC Performance Food Group
$31.41 /

+3.135 (+11.09%)

05/05/20 Guggenheim
Performance Food risk/reward compelling with 50% upside, says Guggenheim
04/23/20 BMO Capital
Performance Food downgraded to Market Perform from Outperform at BMO Capital
04/20/20 Credit Suisse
Performance Food Group reinstated with an Outperform at Credit Suisse
03/26/20 Jefferies
Performance Food Group upgraded to Buy from Hold at Jefferies
MGP MGM Growth
$29.02 /

-0.085 (-0.29%)

05/28/20 JPMorgan
MGM Growth LLC conversation 'major catalyst' for shares, says JPMorgan
05/21/20 BofA
MGM Growth upgraded to Buy from Neutral at BofA
05/19/20 Baird
MGM Growth upgraded to Outperform at Baird
05/19/20 Baird
MGM Growth upgraded to Outperform from Neutral at Baird
VIR Vir Biotechnology
$33.16 /

-1.06 (-3.10%)

USFD US Foods
$23.36 /

+2.245 (+10.63%)

TWTR Twitter
$34.86 /

+1.13 (+3.35%)

SYY Sysco
$61.60 /

+3.02 (+5.16%)

REGN Regeneron
$597.27 /

-0.94 (-0.16%)

PFGC Performance Food Group
$31.41 /

+3.135 (+11.09%)

NYT New York Times
$41.50 /

+1 (+2.47%)

NVAX Novavax
$46.22 /

+1.54 (+3.45%)

MRNA Moderna
$58.16 /

-2.44 (-4.03%)

MGP MGM Growth
$29.02 /

-0.085 (-0.29%)

LLY Eli Lilly
$149.21 /

-1.44 (-0.96%)

GSK GlaxoSmithKline
$41.69 /

+0.04 (+0.10%)

GILD Gilead
$76.67 /

-0.85 (-1.10%)

FMC FMC Corporation
$103.29 /

+3.59 (+3.60%)

FB Facebook
$230.64 /

+4.38 (+1.94%)

AZN AstraZeneca
$53.87 /

+ (+0.00%)

VIR Vir Biotechnology
$33.16 /

-1.06 (-3.10%)

TWTR Twitter
$34.86 /

+1.13 (+3.35%)

SYY Sysco
$61.60 /

+3.02 (+5.16%)

REGN Regeneron
$597.27 /

-0.94 (-0.16%)

NYT New York Times
$41.50 /

+1 (+2.47%)

NVAX Novavax
$46.22 /

+1.54 (+3.45%)

MRNA Moderna
$58.16 /

-2.44 (-4.03%)

MGP MGM Growth
$29.02 /

-0.085 (-0.29%)

LLY Eli Lilly
$149.21 /

-1.44 (-0.96%)

GSK GlaxoSmithKline
$41.69 /

+0.04 (+0.10%)

GILD Gilead
$76.67 /

-0.85 (-1.10%)

FMC FMC Corporation
$103.29 /

+3.59 (+3.60%)

FB Facebook
$230.64 /

+4.38 (+1.94%)

AZN AstraZeneca
$53.87 /

+ (+0.00%)

VIR Vir Biotechnology
$33.16 /

-1.06 (-3.10%)

USFD US Foods
$23.36 /

+2.245 (+10.63%)

TWTR Twitter
$34.86 /

+1.13 (+3.35%)

SYY Sysco
$61.60 /

+3.02 (+5.16%)

REGN Regeneron
$597.27 /

-0.94 (-0.16%)

PFGC Performance Food Group
$31.41 /

+3.135 (+11.09%)

NYT New York Times
$41.50 /

+1 (+2.47%)

MRNA Moderna
$58.16 /

-2.44 (-4.03%)

LLY Eli Lilly
$149.21 /

-1.44 (-0.96%)

GSK GlaxoSmithKline
$41.69 /

+0.04 (+0.10%)

GILD Gilead
$76.67 /

-0.85 (-1.10%)

FMC FMC Corporation
$103.29 /

+3.59 (+3.60%)

FB Facebook
$230.64 /

+4.38 (+1.94%)

AZN AstraZeneca
$53.87 /

+ (+0.00%)

VIR Vir Biotechnology
$33.16 /

-1.06 (-3.10%)

TWTR Twitter
$34.86 /

+1.13 (+3.35%)

SYY Sysco
$61.60 /

+3.02 (+5.16%)

REGN Regeneron
$597.27 /

-0.94 (-0.16%)

NYT New York Times
$41.50 /

+1 (+2.47%)

NVAX Novavax
$46.22 /

+1.54 (+3.45%)

MRNA Moderna
$58.16 /

-2.44 (-4.03%)

GSK GlaxoSmithKline
$41.69 /

+0.04 (+0.10%)

GILD Gilead
$76.67 /

-0.85 (-1.10%)

FMC FMC Corporation
$103.29 /

+3.59 (+3.60%)

FB Facebook
$230.64 /

+4.38 (+1.94%)

AZN AstraZeneca
$53.87 /

+ (+0.00%)

Periodicals
Antibody drugs could help curb pandemic, Barron's says » 09:40
06/06/20
06/06
09:40
06/06/20
09:40
GSK

GlaxoSmithKline

$41.69 /

+0.04 (+0.10%)

, VIR

Vir Biotechnology

$33.16 /

-1.06 (-3.10%)

, LLY

Eli Lilly

$149.21 /

-1.44 (-0.96%)

, REGN

Regeneron

$597.27 /

-0.94 (-0.16%)

, NVAX

Novavax

$46.22 /

+1.54 (+3.45%)

, MRNA

Moderna

$58.16 /

-2.44 (-4.03%)

Chasing COVID-19 vaccine…

Chasing COVID-19 vaccine news has sent investors on a wild ride this spring, as shares of biotechs like Moderna (MRNA) and Novavax (NVAX) have spiked one day and crashed the next, Josh Nathan-Kazis writes in this week's edition of Barron's. Over the next few months, a handful of pharmaceutical companies plan to begin testing a new category of drugs designed to treat, or even prevent, a COVID-19 infection. Called monoclonal antibodies, the drugs mimic the proteins a human body would make to fight the virus that causes COVID-19, and while they don't hold out the promise of eliminating the threat of COVID-19 in the way that an effective vaccine could, the new antibodies could help curb the pandemic, he notes. This summer, at least three programs aim to begin testing their antibodies in humans, namely Eli Lilly (LLY), Regeneron Pharmaceuticals (REGN), and a collaboration between Vir Biotechnology (VIR) and GlaxoSmithKline (GSK). Reference Link

ShowHide Related Items >><<
VIR Vir Biotechnology
$33.16 /

-1.06 (-3.10%)

REGN Regeneron
$597.27 /

-0.94 (-0.16%)

NVAX Novavax
$46.22 /

+1.54 (+3.45%)

MRNA Moderna
$58.16 /

-2.44 (-4.03%)

LLY Eli Lilly
$149.21 /

-1.44 (-0.96%)

GSK GlaxoSmithKline
$41.69 /

+0.04 (+0.10%)

GSK GlaxoSmithKline
$41.69 /

+0.04 (+0.10%)

05/14/20 UBS
GlaxoSmithKline price target raised to 1,920 GBp from 1,900 GBp at UBS
05/05/20 JPMorgan
GlaxoSmithKline price target lowered to 1,700 GBp from 1,750 GBp at JPMorgan
04/30/20 Barclays
GlaxoSmithKline price target raised to 1,550 GBp from 1,450 GBp at Barclays
03/11/20 JPMorgan
JPMorgan backs Neutral on GSK after 2019 annual report
VIR Vir Biotechnology
$33.16 /

-1.06 (-3.10%)

05/13/20 Barclays
Vir Biotechnology price target raised to $44 from $41 at Barclays
03/19/20 JPMorgan
JPMorgan downgrades Vir Biotechnology to Underweight after 290% rally
03/19/20 JPMorgan
Vir Biotechnology downgraded to Underweight from Neutral at JPMorgan
03/13/20 Goldman Sachs
Vir Biotechnology downgraded to Neutral from Buy at Goldman Sachs
LLY Eli Lilly
$149.21 /

-1.44 (-0.96%)

06/05/20 Piper Sandler
Nektar sees 'encouraging trends' in early lupus trial, says Piper Sandler
06/02/20 JPMorgan
JPMorgan positions for second half with three picks in Major Pharma
06/01/20 Morgan Stanley
Lilly trial has higher risk and reward after Pfizer failure, says Morgan Stanley
05/29/20 Raymond James
Blueprint approval for pralsetinib could come before PDUFA, says Raymond James
REGN Regeneron
$597.27 /

-0.94 (-0.16%)

06/02/20 Cantor Fitzgerald
Regeneron price target raised to $624 from $400 at Cantor Fitzgerald
05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Barclays
Regeneron price target raised to $615 from $530 at Barclays
05/27/20 Citi
BioMarin a good takeout candidate, but not by Sanofi, says Citi
NVAX Novavax
$46.22 /

+1.54 (+3.45%)

06/05/20
Fly Intel: Top five analyst upgrades
06/05/20 JPMorgan
JPMorgan upgrades Novavax to Neutral despite 'shaky fundamentals'
06/05/20 B. Riley FBR
Novavax price target raised to $74 from $61 at B. Riley FBR
06/05/20 JPMorgan
Novavax upgraded to Neutral from Underweight at JPMorgan
MRNA Moderna
$58.16 /

-2.44 (-4.03%)

06/02/20 Piper Sandler
Piper reiterates Overweight rating, $100 target for Moderna after Science Day
06/02/20 BofA
Moderna price target lowered to $75 from $80 at BofA
06/01/20 Goldman Sachs
Goldman keeps $105 target after Moderna COVID vaccine moves to Phase 2
05/26/20 Maxim
ADMA Biologics' use of plasma is 'oldest trick in pandemic playbook', says Maxim
VIR Vir Biotechnology
$33.16 /

-1.06 (-3.10%)

REGN Regeneron
$597.27 /

-0.94 (-0.16%)

NVAX Novavax
$46.22 /

+1.54 (+3.45%)

MRNA Moderna
$58.16 /

-2.44 (-4.03%)

LLY Eli Lilly
$149.21 /

-1.44 (-0.96%)

GSK GlaxoSmithKline
$41.69 /

+0.04 (+0.10%)

VIR Vir Biotechnology
$33.16 /

-1.06 (-3.10%)

REGN Regeneron
$597.27 /

-0.94 (-0.16%)

NVAX Novavax
$46.22 /

+1.54 (+3.45%)

MRNA Moderna
$58.16 /

-2.44 (-4.03%)

LLY Eli Lilly
$149.21 /

-1.44 (-0.96%)

GSK GlaxoSmithKline
$41.69 /

+0.04 (+0.10%)

VIR Vir Biotechnology
$33.16 /

-1.06 (-3.10%)

REGN Regeneron
$597.27 /

-0.94 (-0.16%)

NVAX Novavax
$46.22 /

+1.54 (+3.45%)

LLY Eli Lilly
$149.21 /

-1.44 (-0.96%)

GSK GlaxoSmithKline
$41.69 /

+0.04 (+0.10%)

VIR Vir Biotechnology
$33.16 /

-1.06 (-3.10%)

REGN Regeneron
$597.27 /

-0.94 (-0.16%)

NVAX Novavax
$46.22 /

+1.54 (+3.45%)

MRNA Moderna
$58.16 /

-2.44 (-4.03%)

GSK GlaxoSmithKline
$41.69 /

+0.04 (+0.10%)

Hot Stocks
Vir Biotechnology, Biogen enter agreement to manufacture SARS-CoV-2 antibodies » 08:23
05/29/20
05/29
08:23
05/29/20
08:23
VIR

Vir Biotechnology

$31.58 /

-0.62 (-1.93%)

, BIIB

Biogen

$300.49 /

-0.98 (-0.33%)

Vir Biotechnology, Inc.…

Vir Biotechnology, Inc. (VIR) announced that is has finalized a process development and manufacturing agreement with Biogen Inc. (BIIB) based on the letter of intent that the companies announced in March. Under the agreement Biogen will perform process development activities and specified manufacturing and process transfer services to enable commercial supply of Vir's SARS-CoV-2 monoclonal antibodies. Vir's SARS-CoV-2 antibody development candidates, VIR-7831 and VIR-7832, have demonstrated high affinity for the SARS-CoV-2 spike protein and the ability to neutralize SARS-CoV-2 in live-virus cellular assays. The execution of this definitive agreement allows Vir to advance the development of its antibody candidates and complements its existing manufacturing agreements with WuXi Biologics and Samsung Biologics. Under the terms of the agreement, Biogen and Vir will collaborate to develop highly productive clonal cell lines and clinical and commercial manufacturing processes for Vir's SARS-CoV-2 antibody candidates. These processes are designed to be transferrable to global biomanufacturing facilities designed for advanced biologics production. As part of the agreement, Vir has contracted with Biogen to conduct cGMP clinical manufacturing in the U.S. and provide technical support to facilitate rapid process transfer to Samsung Biologics, and potentially other large-scale biomanufacturing facilities in the U.S. and all other regions of the globe in order to provide reliable supply of a potential commercial product.

ShowHide Related Items >><<
VIR Vir Biotechnology
$31.58 /

-0.62 (-1.93%)

BIIB Biogen
$300.49 /

-0.98 (-0.33%)

VIR Vir Biotechnology
$31.58 /

-0.62 (-1.93%)

05/13/20 Barclays
Vir Biotechnology price target raised to $44 from $41 at Barclays
03/19/20 JPMorgan
JPMorgan downgrades Vir Biotechnology to Underweight after 290% rally
03/19/20 JPMorgan
Vir Biotechnology downgraded to Underweight from Neutral at JPMorgan
03/13/20 Goldman Sachs
Vir Biotechnology downgraded to Neutral from Buy at Goldman Sachs
BIIB Biogen
$300.49 /

-0.98 (-0.33%)

04/23/20
Fly Intel: Top five analyst downgrades
04/23/20 Oppenheimer
Biogen price target lowered to $365 from $390 at Oppenheimer
04/23/20 Raymond James
Biogen downgraded to Underperform from Market Perform at Raymond James
04/23/20 Jefferies
Biogen may lack catalysts until more aducanumab clarity, says Jefferies
VIR Vir Biotechnology
$31.58 /

-0.62 (-1.93%)

BIIB Biogen
$300.49 /

-0.98 (-0.33%)

VIR Vir Biotechnology
$31.58 /

-0.62 (-1.93%)

BIIB Biogen
$300.49 /

-0.98 (-0.33%)

VIR Vir Biotechnology
$31.58 /

-0.62 (-1.93%)

BIIB Biogen
$300.49 /

-0.98 (-0.33%)

VIR Vir Biotechnology
$31.58 /

-0.62 (-1.93%)

BIIB Biogen
$300.49 /

-0.98 (-0.33%)

Hot Stocks
Vir Biotechnology initiates Phase 1 trial of VIR-3434 for chronic HBV » 08:16
05/27/20
05/27
08:16
05/27/20
08:16
VIR

Vir Biotechnology

$33.62 /

-0.1 (-0.30%)

Vir Biotechnology…

Vir Biotechnology announced the initiation of a Phase 1 clinical trial of VIR-3434, an investigational monoclonal antibody that neutralizes hepatitis B virus and has been engineered to potentially also act as a therapeutic vaccine. The commencement of first-in-human dosing marks the start of Vir's second clinical program aimed at a functional cure for HBV. VIR-3434 is an HBV-neutralizing monoclonal antibody designed to block entry of all 10 genotypes of HBV into hepatocytes, and also to reduce the level of virions and subviral particles in the blood. It has also been Fc engineered to include the XX2 "vaccinal mutation," for which Vir has licensed exclusive rights for all infectious diseases. VIR-2218, an investigational small interfering ribonucleic acid that mediates RNA interference, is currently being investigated in a Phase 2 trial for the treatment of chronic HBV infection. The Phase 1 clinical trial of VIR-3434 is a randomized, placebo-controlled trial designed to assess the safety, tolerability, pharmacokinetics, antiviral and immunomodulatory activity of VIR-3434 in healthy volunteers and patients with chronic HBV infection. The company plans to enroll patients at multiple trial sites in several countries in the Asia Pacific and European regions. The trial is designed to progress from healthy volunteers to chronic HBV patients in a staggered, parallel fashion with the goal of rapidly generating early proof-of-concept data in patients. Data are expected to be available in 2021.

ShowHide Related Items >><<
VIR Vir Biotechnology
$33.62 /

-0.1 (-0.30%)

VIR Vir Biotechnology
$33.62 /

-0.1 (-0.30%)

05/13/20 Barclays
Vir Biotechnology price target raised to $44 from $41 at Barclays
03/19/20 JPMorgan
JPMorgan downgrades Vir Biotechnology to Underweight after 290% rally
03/19/20 JPMorgan
Vir Biotechnology downgraded to Underweight from Neutral at JPMorgan
03/13/20 Goldman Sachs
Vir Biotechnology downgraded to Neutral from Buy at Goldman Sachs
VIR Vir Biotechnology
$33.62 /

-0.1 (-0.30%)

VIR Vir Biotechnology
$33.62 /

-0.1 (-0.30%)

VIR Vir Biotechnology
$33.62 /

-0.1 (-0.30%)

VIR Vir Biotechnology
$33.62 /

-0.1 (-0.30%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.